In-Vivo Gene Editing for Retinal Disease: Current Status and Future Prospects

Abstract

Recent advancements in in-vivo gene editing offer transformative potential for the management of inherited and acquired retinal diseases. This review synthesizes current scientific and clinical evidence on gene editing modalities, focusing on their mechanisms, efficacy, safety, and translational implications in ophthalmology. The article provides clinicians and researchers with a comprehensive overview of epidemiology, pathophysiology, clinical features, diagnosis, management, and the latest developments in gene therapy, with special emphasis on guideline-based recommendations and future directions.

Introduction

Retinal diseases, encompassing a spectrum from inherited retinal dystrophies to acquired degenerative conditions, represent a significant cause of vision impairment globally. Traditional management strategies have often focused on symptom alleviation rather than disease modification. The advent of in-vivo gene editing technologies, such as CRISPR-Cas systems, has created unprecedented opportunities for targeted, disease-modifying interventions. This article aims to provide a detailed review of the scientific basis, clinical utility, and emerging trends in in-vivo gene editing for retinal disorders, guiding clinicians in evidence-based decision-making.

Epidemiology / Disease Burden

Inherited retinal diseases (IRDs) affect approximately 1 in 3,000 individuals worldwide, with retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) among the most prevalent. Age-related macular degeneration (AMD) and diabetic retinopathy represent leading causes of acquired retinal dysfunction, especially in aging populations and those with metabolic comorbidities. The global burden of retinal blindness is projected to increase with rising life expectancy and prevalence of diabetes, underscoring the need for curative therapies.

Pathophysiology

Retinal diseases can result from a wide array of genetic mutations affecting photoreceptors, retinal pigment epithelium, or supporting vasculature. Inherited disorders typically involve loss-of-function or gain-of-function mutations in genes essential for phototransduction, metabolic stability, or retinal structure. Acquired conditions, such as AMD, involve oxidative stress, inflammation, and neovascularization. The highly compartmentalized and immune-privileged nature of the eye makes it an ideal target for gene editing interventions, minimizing systemic exposure and immune responses.

Risk Factors

Risk factors for retinal diseases are multifactorial. For IRDs, autosomal dominant, autosomal recessive, and X-linked inheritance patterns are common, with over 250 genes implicated. Acquired retinal disorders are associated with aging, metabolic syndrome, hypertension, smoking, and genetic susceptibility loci, such as complement factor H in AMD. Understanding these risk profiles informs both patient selection and therapeutic targeting for gene editing approaches.

Clinical Features

Clinical manifestations vary by disease etiology. IRDs typically present with progressive night blindness, peripheral vision loss, and eventual central vision impairment. AMD is characterized by drusen formation, pigmentary changes, and, in neovascular forms, subretinal hemorrhage and scarring. Diabetic retinopathy features microaneurysms, hemorrhages, and neovascularization. Accurate phenotypic characterization is essential for precise gene therapy targeting and monitoring therapeutic outcomes.

Diagnosis

Diagnosis of retinal diseases integrates multimodal imaging (optical coherence tomography, fundus autofluorescence), functional testing (visual fields, electroretinography), and increasingly, molecular genetic testing. Next-generation sequencing (NGS) enables identification of causative mutations in IRDs, guiding eligibility for gene editing trials. Ancillary laboratory and imaging studies help distinguish acquired from inherited etiologies and inform prognosis.

Treatment & Management

Conventional management of retinal diseases includes pharmacologic interventions (anti-VEGF agents for AMD, corticosteroids for macular edema), laser photocoagulation, and low vision rehabilitation. However, these modalities do not address the underlying genetic defects. Gene replacement therapy (e.g., voretigene neparvovec for RPE65-mediated LCA) marked a paradigm shift, but challenges persist, including vector limitations and immune responses. In-vivo gene editing aims to permanently correct pathogenic mutations at the DNA level, offering the prospect of durable disease modification.

Recent Advances / Emerging Therapies

The CRISPR-Cas9 system, base editors, and prime editing platforms have demonstrated preclinical and early clinical success in correcting mutations responsible for IRDs. Notably, EDIT-101, a CRISPR-based therapy targeting CEP290 mutations in LCA10, has shown promising safety and preliminary efficacy in phase 1/2 trials. Delivery modalities include adeno-associated virus (AAV) vectors and non-viral nanoparticles, with subretinal and intravitreal injection routes under investigation. Off-target effects, immunogenicity, and mosaicism remain key concerns, necessitating rigorous long-term follow-up in clinical studies. Advances in gene editing specificity, such as high-fidelity Cas variants and RNA-guided base editors, are actively being explored to enhance safety profiles.

Guideline Recommendations

Current clinical guidelines from organizations such as the American Academy of Ophthalmology and the American Society of Gene & Cell Therapy recommend that gene editing interventions be considered within the context of well-designed clinical trials. Patient selection should be guided by molecular diagnosis, disease stage, and residual retinal function. Informed consent must address potential risks, including unforeseen genetic alterations and immune reactions. Multidisciplinary collaboration among geneticists, ophthalmologists, and ethicists is emphasized to optimize patient outcomes and monitor for adverse events.

Conclusion

In-vivo gene editing represents a frontier in the management of retinal diseases, offering the potential for precise, durable, and potentially curative interventions. Early-phase clinical data suggest feasibility and safety, but further studies are needed to validate efficacy, long-term safety, and cost-effectiveness. Ongoing advancements in gene editing technology and delivery systems are poised to expand therapeutic options for patients with previously untreatable retinal conditions. Integration of robust clinical guidelines and multidisciplinary expertise will be critical to realizing the full potential of gene editing in ophthalmology.